DAVITA INC. (DVA) Stock News

DaVita HealthCare (DVA) closed at $187.25, down 1.01% in the latest session but outperforming the S&P 500's 1.09% decline. The kidney dialysis provider is forecasted to report EPS of $3.78 (up 50.6% YoY) with revenue expected at $3.53 billion (up 3.23% YoY). Trading at a Forward P/E of 12.98 versus the industry average of 20.96, DVA appears undervalued. The stock holds a Zacks Rank #3 (Hold) with a PEG ratio of 0.49, significantly below the industry average of 1.82.

A class action lawsuit has been filed against Aardvark Therapeutics in the U.S. District Court for the Southern District of California. The lawsuit alleges that defendants made materially false and misleading statements in the company's IPO registration statement and throughout the class period (February 13, 2025 to May 14, 2026), specifically regarding the safety and commercial prospects of their drug ARD-101. Investors who purchased shares during this period can apply to be lead plaintiff by October 13, 2026.

DaVita HealthCare (DVA) closed at $179.25, up 1.26% and outperforming the S&P 500. The kidney dialysis provider is projected to report 50.6% EPS growth and 3.23% revenue growth in the upcoming quarter, with full-year estimates showing 35.16% earnings growth. Trading at a Forward P/E of 12.15 (below industry average of 20.06) and a PEG ratio of 0.46, DVA holds a Zacks Rank #3 (Hold) rating.

Rosen Law Firm announces a securities class action lawsuit against Aardvark Therapeutics, with an October 13, 2026 deadline for investors to serve as lead plaintiff. The lawsuit alleges that defendants made materially false and misleading statements regarding the safety and prospects of their drug candidate ARD-101, causing investor damages when the true details emerged.

DaVita HealthCare (DVA) closed at $178.69, up 1.33%, outperforming the S&P 500's 0.73% gain. The kidney dialysis provider is projected to report earnings of $3.78 per share with 50.6% year-over-year growth. The stock trades at a Forward P/E of 12.1, below the industry average of 19.68, and holds a Zacks Rank of #3 (Hold) with a PEG ratio of 0.46, indicating potential value.

Rosen Law Firm has announced multiple securities class action lawsuits against Aardvark Therapeutics, FuelCell Energy, and XTI Aerospace. The primary case involves Aardvark Therapeutics, where investors claim the company made materially false statements about the safety and prospects of its ARD-101 drug candidate in its IPO registration statement and throughout the class period. Investors have until October 13, 2026 to become lead plaintiffs in the Aardvark case.

Rosen Law Firm is reminding investors in Aardvark Therapeutics, Inc. (AARD) of an October 13, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that Aardvark made materially false and misleading statements regarding the safety and prospects of its drug ARD-101, causing investor damages when the truth entered the market. The firm is also investigating claims related to Hyliion Holdings Corp. (HYLN) and FLOW cryptocurrency.

The Rosen Law Firm announced a securities class action lawsuit against Aardvark Therapeutics, Inc. (AARD) for allegedly making false and misleading statements regarding the safety profile of its drug ARD-101 and overstating its clinical, regulatory, and commercial prospects. The lawsuit covers investors who purchased securities between February 13, 2025 (IPO date) and May 14, 2026. The deadline to file a claim is October 13, 2026.

Dimensional Fund Advisors Ltd. disclosed a 1.41% stake in Advanced Medical Solutions Group PLC comprising 3,110,204 ordinary shares as of June 22, 2026. The disclosure includes a single purchase transaction of 112 shares at 22.3150 GBP per unit. Dimensional expressly disclaims beneficial ownership and notes it lacks discretion over 32,163 of the disclosed shares.

Sika has appointed Philipp Irniger as Head of Construction and Group Management member, effective June 1, 2026, succeeding Ivo Schädler who is retiring. Additionally, Sika created a new Chief Digital & Information Officer position to accelerate its digital transformation strategy and strengthen its digital leadership in the industry.

Protara Therapeutics reported positive 12-month efficacy and safety data from its Phase 2 ADVANCED-2 trial of TARA-002 in BCG-naïve non-muscle invasive bladder cancer patients, demonstrating a 55% complete response rate at 12 months with no Grade 3 or greater adverse events. The company plans to initiate the registrational ADVANCED-3 trial in the second half of 2026 and submit a BLA for TARA-002 in lymphatic malformations in 2H 2027.

Buscar Company (CGLD) announced significant progress in permitting for its Treasure Canyon Gold Mine project in Plumas County, California. The company has received multiple approvals including a burn permit from the Northern Sierra Air Quality Management District and a Lake and Streambed Alteration Agreement from the California Department of Fish and Wildlife. The project continues advancing through federal and state regulatory reviews with ongoing coordination among agencies.

Armlogi Holding Corp. announced the next phase of its internal middle-mile transportation initiative, focusing on leveraging its network to enhance service levels for over 600 merchant clients, improve operational utilization, and support long-term efficiency gains. The company is transitioning from converting outsourced transportation to building an integrated operational platform that offers imp